One big reason is the debt offering. Market cap needed to get to a lower level and nobody serious is buying until then. But now it is reasonably priced, about 2-3x last years sales. BUT sales have been increasing rapidly and probably will continue due to more retail partners, esp. BBY. So... last years sales are not the best metric. Therefore... stock is undervalued now if sales grow the way the did last year.
Second reason is the decline in oil. Like it or not ASTI is solar and therefore tied to energy sectore. But...this is complete nonsense b/c consumers don't buy their product as an alternative to oil/pluggin into the grid. What applies to panel makers who are selling product for these uses does not apply to gadget maker ASTI. ASTI product is strictly as a convenience, novelty, protective case, extra battery, travel assesory...and so on and so forth. So, tons of reasons for people to buy the gadgets. Problem is that the quality isn't what it could be. The best selling point is the thinness and weight.
This has nothing to do with bankruptcy anytime soon as many seem to be thinking. ASTI has plenty of cash available now. The next few earnings reports will be important to gauge the effect of the new retailers. So...no reason to panic right now.
We just went through the rinse job, so NVAX is primed to rip through 52wk high. The only thing that could stop it is a nasty overall market correction. If market is green, NVAX looks like it could breakout $2-3 dollars. The recent deep pullback over the past few months makes it all the better.
The pipeline keeps growing and they keep getting closer to approval of the all-important RSV vaccine. As far as I can tell there isn't even any hype yet, just technical traders watching it due to chart setup, volatility and Friday's big move. so this is just the anticipatory smart-money move IMO.
So in other words, youz getting crushed by the shorts just like everybody else.
"averaged down" on stock of a company with no foundation...
Just like any good naive investor would do
I think somebody is running out of options.
The Russian government (which I think we all know is troubled right now) has to build the Skolkovo Innovation Center first. Only then can they bio-print some organs.
Nice try rappy.
" I won't be taking it from anyone on a message board...particularly a midget with a temper"
haha! Well said. Taylor here will probably change his alias again soon (for the 3rd or 4th time, lol). So now's the time for everyone to speak their mind about him.
Yeah taylor, that's exactly right. If only Roche had tested Geron's tissue things would have been so completely different. That's really all that was needed. How stupid of them not to think of that. LOL
GERN is just one example, taylor. There are many other overhyped biotechs which soared and roared then crash and burned. Would you like me to provide a list of all the biotechs that are down 75% or more over the last year period?
Take a look at GERN spike when hype clouded judgement....
They were probably "growing" them using stem cells. Stem cells probably hold more promise for growing organs. It's even possible that extra organs could be grown inside our own bodies, using stem cells. Ironically, stem cells stocks were all the rage over 10 years ago. GERN was the granddaddy of them all. Nothing panned out for GERN in the stem cell game so it actually switched its focus to cancer drugs. But, at its hyped-up peak GERN sported an insane valuation. Then the bear market hit and its share price was nearly obliterated.
george, you are correct sir. The job boards offer no actionable info. It's a favorite topic of convo on the message boards when there's not much going on....people start looking for something, anything, that might be viewed as a positive. One result is that expenses will go up. That's not exactly a positive.
What's more important is who they're recruiting. Are they getting Phds from MIT, Harvard, Stanford? or are they getting B.S.s from U of Oklahoma?
"baseline market cap for a biotech that shows outstanding promise but has not reported revenue yet is around the $500 million level"
That's probably about right in the current bull market environment. But, you'll also find a lot of them have substantial revenues already from existing pipelines or from contract revenue/collaborations. ONVO, trading at 1000x+ revenue is an anomaly in this sense. And I'm not making this up. Run a scan with the sales multiple as your primary metric and you'll find ONVO near the top along with some other controvertial names.
Furthermore, as I've said before, it's a bull market story stock. The spec names in biotech won't hold up over $500mil market cap in a bear market. These issues will be the first to plunge if the broad market goes bear.
So, do you think the bull market will last 10 more years (the time it will take for us to find out whether ONVOs path was a success or a failure).
Finally a good sensible article on the subject of ONVO. It's not overly a bash piece. The author weights the good along with the bad and comes to a logical conclusion. Disclosure: It's the same conclusion I've drawn (which just happens to be the right one). Basically, it's a problem of time. Could ONVO eventually churn organs out a 3d printer? Sure, it's certainly a nice dream, but still in the dream stage. Millions if not billions of dollars will be spent to turn dream into reality. And by then, there could be dozens of other viable options and worthy competition.
I also couldn't help but notice that the author has a solid track record...67% accuracy or something like that.
"a major disruption" haha. Yeah right, Taylor.
Taylor, the landscape of $1 or less stocks is littered with old bull market story stocks. They were all "going to cause a major disruption".
One of them is Dr. Presnell's former employer. They were going to disrupt regenerative medicine. LOL.
Keep me laughing Taylor, just keep me laughing.
Yeah, 100 shares or less....SMALL money in the overall scheme of things.
Sure, market makers and ECNs will play some games. That's just their job. But if you're long term, why would you care?
No, the only hindrance is SELLERS. And short sellers make up a small percentage of that total. So, you should really be blaming your fellow longs for taking profits/cutting losses. ONVO is still down on 1 year performance. And a long ways off the all time highs.
As a short, I look forward to the quarterly report. Even if they managed to sell a couple of their tissue models, we're still looking at an absurd valuation. If no sales, no good.
But I like to make predictions based on past trends. And earnings reports has never been much of a catalyst for ONVO stock. ONVO is a bull market story stock, nothing more. When enthusiasm dries up/market corrects, this will be a crash on steroids.
P.S We shorts don't like range bound situations either. Nobody does unless your just trading the range. But it's a little late to be doing that now, IMHO